HP Enterprise initiated with a Buy at Jefferies » 08:1304/2004/20/21
Jefferies analyst Kyle…
Mesa Air price target raised to $14 from $10 at Raymond James » 07:2804/2004/20/21
Raymond James analyst…
Iridium reaffirms FY21 revenue view up 3% from $463.1M lst year » 07:0504/2004/20/21
The Company reiterated…
Iridium reports Q1 EPS(4c) , consensus (5c) » 07:0304/2004/20/21
Reports Q1 revenue…
Tradeweb Markets price target raised to $80 from $69 at Citi » 05:5604/2004/20/21
Citi analyst Ben Herbert…
Integra LifeSciences issues statement on FDA communication on ADM products » 16:1904/1904/19/21
Integra LifeSciences issued the following statement regarding the FDA safety communication on the differences in complication rates between acellular dermal matrix, or ADM, products used in implant-based breast reconstruction: "Integra LifeSciences supports the efforts of the U.S. FDA to protect women's health, including its recent safety communication on ADM products used in implant-based breast reconstruction. SurgiMend Collagen Matrix is currently cleared by the FDA for use in certain types of surgeries to reinforce tissue where weakness exists, such as plastic and reconstructive surgery, and hernia repair. Neither SurgiMend nor any other ADM (human or xenograft) is currently approved for use in breast reconstruction in the United States. It is important for patients to discuss the use of medical technologies, including SurgiMend, with their healthcare providers. Integra is committed to delivering safe and effective medical technologies and products to our customers and their patients, including securing clearance or approval for a product indicated for breast reconstruction. We work to consistently meet or exceed industry and global regulatory standards to provide quality products and technologies designed to meet the needs of our customers and their patients. We applaud the ongoing work of the various surgeon associations and patient advocacy groups in reinforcing the importance of quality patient care and promoting education, advocacy, and public awareness of various healthcare issues. Integra continues to collaborate with the clinical community to pursue solutions to advance women's health."
Aflac option volume 44x normal after large spread rolls position » 14:2004/1904/19/21
Aflac option volume 44x…
Aflac option volume 44x normal after large spread rolls position. Shares of the insurance company are little changed today near $53.54 following a large spread on NYSE-Arca where the May 40/50 risk reversal traded against the August 40/57.5 risk reversal 18900x. Net premium was a debit of $3.64, or $6.8M, which opens a protective collar in August using the 25% downside and 7% upside strikes, while the May 40/50 appears to close a position opened in February in a roll from November when shares were nearly $6 below current levels.
SS&C moves forward on acquisition of Mainstream Group » 09:0504/1904/19/21
SS&C announced that…
SS&C announced that the board of directors of Mainstream Group has unanimously recommended an acquisition by SS&C of 100% of the shares and outstanding equity rights in Mainstream for A$2.00 per security pursuant to a scheme of arrangement. The matching rights of Vistra Group in connection with its prior Scheme Implementation Deed have now expired and Mainstream is proceeding to terminate that agreement with Vistra Group in accordance with its terms. SS&C's Scheme Implementation Deed will then become fully operative per its terms. Mainstream is a provider of investment administration, middle office, fund accounting, superannuation administration, share registry and unit registry services to fund managers and superannuation funds, family offices and dealer groups. The company serves clients globally through its offices in Australia, Hong Kong, Singapore, Ireland, Malta, Isle of Man, the Cayman Islands and the U.S. Terms of the proposed acquisition imply an enterprise value for Mainstream of approximately A$296M or approximately $225M. The purchase is expected to close in Q3.
Pioneer Natural price target raised to $190 from $175 at Truist » 08:3404/1904/19/21
Truist analyst Neal…
Truist analyst Neal Dingmann raised the firm's price target on Pioneer Natural to $190 from $175 and keeps a Buy rating on the shares. The company experienced a slight hit from February weather but should still top Q1 consensus estimates, the analyst tells investors in a research note, adding that its DoublePoint acquisition also provides Pioneer with an upcoming "arsenal" to help reach its desired free cash flows and shareholder returns.
Synnex signs distribution agreement with Citrix » 08:3304/1904/19/21
Synnex (SNX) announced a…
Synnex (SNX) announced a new distribution agreement with Citrix (CTXS). Under the terms of agreement, Synnex will provide their partner community with access to Citrix digital workspace solutions. The solutions will immediately be available to partners in the U.S. and Canada through Synnex Stellr.